ADMS News and Press, Adamas Pharmaceuticals Inc. From 12/17/19

"As we did not see the scale of clinical benefit we had hoped for in this study we will fully assess the potential for ADS-5102 in MS patients before determining the extent of our continued investment in this program," says Adamas ( ADMS -40.7% ) CEO Neil McFarlane after mixed results in...

Adamas Pharmaceuticals (NASDAQ: ADMS ) announces positive results from a Phase 3 clinical trial, INROADS , evaluating Gocovri (amantadine) (ADS-5102) in multiple sclerosis (MS) patients with walking impairment. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks o...

- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety data consistent with known safety profile of amantadine - EMERYVILLE, Calif., De...

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS ) investors concerning the Company and its officers’ possible violations of federal securiti...

Adamas Pharmaceuticals ( ADMS ) has taken numerous steps to proliferate GOCOVRI adoption and the numbers are slowly grinding higher. The company’s third-quarter product sales came in a $13.9M, which was a 9% increase over Q2 and a 31% increase over Q3 of last year. Thus far, GOCOVRI h...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with this Read more ...

Gainers: HQY   +11.9% . RAPT   +8.2% . CIH   +8.2% . SIGA   +5.0% . NPO   +4.8% . More news on: HealthEquity, Inc., RAPT Therapeutics, Inc., China Index Holdings Limited, Stocks on the move, Read more ...

EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive...

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2019 Earnings Conference Call November 07, 2019, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Neil McFarlane - CEO & Director Vijay Shreedhar - Chief Commercial Officer Rajiv Patni - Chief Medical Officer Christophe...

The following healthcare companies have file for mixed shelf offerings: More news on: Adamas Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...